Hangzhou Sciwind Biosciences Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Subsidiary
- Established
- 2017-08-17
- Employees
- 11
- Market Cap
- -
- Website
- http://www.sciwind.com.cn
Clinical Trials
6
Active:0
Completed:5
Trial Phases
2 Phases
Phase 1:3
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (50.0%)Phase 3
3 (50.0%)A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT06335134
- Locations
- 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
Phase 3
Completed
- Conditions
- Weight Management
- Interventions
- Drug: Ecnoglutide Medium DosageDrug: PlaceboDrug: Ecnoglutide Low DosageDrug: Ecnoglutide High Dosage
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 664
- Registration Number
- NCT05813795
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05779995
- Locations
- 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
Phase 3
Completed
- Conditions
- Type 2 Diabetes MellitusT2DM
- Interventions
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 623
- Registration Number
- NCT05680129
- Locations
- 🇨🇳
ZHONGSHAN Hospital, Shanghai, Shanghai, China
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 211
- Registration Number
- NCT05680155
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
- Prev
- 1
- 2
- Next
News
No news found